Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
DURHAM, N.C., March 01, 2016 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will present at the 36th Annual Cowen and Company Health Care Conference on Tuesday, March 8, 2016 at 8:00 a.m. ET at the Boston Marriott Copley Place.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at http://ir.chimerix.com/events.cfm, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals to address unmet medical needs. Chimerix's proprietary lipid conjugate technology has produced brincidofovir, a clinical-stage nucleotide analog, CMX157 which was licensed to ContraVir Pharmaceuticals in 2014, and early clinical candidates including CMX669. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT: Investor Relations: [email protected] or Jesse Baumgartner Stern Investor Relations [email protected] 212-362-1200 Media: Becky Vonsiatsky W2O Group [email protected] 413-478-2003
